选择语言

Biotinylated Human B7-H3 (4Ig) / B7-H3b Protein, His,Avitag™ (MALS verified)

用户评价
货号-规格
价格
Qty.
B7B-H82E8-25ug
¥3675.00
B7B-H82E8-200ug
¥14490.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    4Ig-B7-H3,B7-H3,CD276,PSEC0249,UNQ309,PRO352,B7 homolog 3

  • 表达区间及表达系统(Source)

    Biotinylated Human B7-H3 (4Ig), His,Avitag (B7B-H82E8) is expressed from human 293 cells (HEK293). It contains AA Gly 27 - Thr 461 (Accession # Q5ZPR3-1).

    Predicted N-terminus: Gly 27

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    B7-H3 (4Ig) Structure

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 50.3 kDa. The protein migrates as 65-80 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 偶联(Conjugate)

    Biotin

  • 标记(Labeling)

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • 内毒素(Endotoxin)

    Less than 1.0 EU per μg by the LAL method.

  • 纯度(Purity)

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

产品展示

  • 电泳(SDS-PAGE)

    B7-H3 (4Ig) SDS-PAGE

    Biotinylated Human B7-H3 (4Ig), His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    B7-H3 (4Ig) SEC-MALS

    The purity of Biotinylated Human B7-H3 (4Ig), His,Avitag (Cat. No. B7B-H82E8) is more than 90% and the molecular weight of this protein is around 60-70 kDa verified by SEC-MALS.

    Report
  • 活性(Bioactivity)-ELISA

     B7-H3 (4Ig) ELISA

    Immobilized Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Biotinylated Human B7-H3 (4Ig), His,Avitag (Cat. No. B7B-H82E8) with a linear range of 0.3-2 ng/mL (QC tested).

    Protocol
  •  B7-H3 (4Ig) ELISA

    Immobilized Biotinylated Human B7-H3 (4Ig), His,Avitag (Cat. No. B7B-H82E8) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.3-5 ng/mL (Routinely tested).

    Protocol
  • 活性(Bioactivity)-FACS

     B7-H3 (4Ig) FACS

    2e5 of anti-B7-H3 CAR-293 cells were stained with 100 μL of 0.3 μg/mL of Biotinylated Human B7-H3 (4Ig), His,Avitag (Cat. No. B7B-H82E8) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).

    Protocol

用户评价
发表评论

背景介绍

Human B7 homolog 3 (B7-H3) is a member of the B7 family of immune proteins that provide signals for the regulation of immune responses. Other family members include B7-1, B7-2, B7-H1/PD-L1, B7-H2, and PD-L2. B7 family proteins are type I transmembrane immunoglobulin (Ig) superfamily members that contain extracellular Ig V‑like and Ig C‑like domains with a short cytoplasmic tail. Termed 4IgB7-H3 or B7-H3b, this molecule has two additional Ig-like domains (one V‑type and one C‑type) and shows a ubiquituous expression pattern.

前沿进展

 
药物研发进展
  • 英文全称:

    CD276 antigen

  • 中文全称:

    CD276抗原

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    45 详情

  • 最高研发阶段:

    申请上市

联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍